2025 · 4th Quarter (Oct 1 - Dec 31)

BIOTECHNOLOGY INNOVATION ORGANIZATION (FORMERLY BIOTECHNOLOGY INDUSTRY ORG.)

Filed by CAPITOL COUNSEL LLC.

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 18, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: CAPITOL COUNSEL LLC
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (FORMERLY BIOTECHNOLOGY INDUSTRY ORG.)
Filing UUID: 695d5c81-500d-4bb3-b1ef-e3e22f229ece
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Medicare Part B coverage and reimbursement issues for biotechnology treatments and issues related to the Medicare Part D coverage, including issues found in H.R. 1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21

Literal federal measure citations: H.R. 1

TAX · Taxation/Internal Revenue Code

Legislative and regulatory issues affecting innovation, including vaccines.

TRD · Trade (domestic/foreign)

Issues related to tarriffs.

BUD · Budget/Appropriations

Items related to USDA, FDA, genetic engineering, and regulations associated with biotechnology in the Agriculture/Rural Development/Food and Drug Administration proposed Appropriation measures for FY 2026 (House/Senate).

HCR · Health Issues

Public health issues impacting patient access to treatments. Updates and reforms to regulation of treatment development and research.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.